Atopic DermatitisREACH-ADNCT06421740
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
An observational study of Atopic Dermatitis, run by AbbVie at 38 sites in China.
Trial summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up… Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Atopic Dermatitis
- How many people
- 1,000 participants
- Where
- 38 sitesChina
- Study dates
- 7 Jun 2024to 25 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
Who may be able to join
- Adolescents (body weight >= 40 kg at the Baseline Visit for patients between >= 12 and < 18 years of age) and adults at the time of enrollment.
- Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
- UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC.
- The decision to prescribe UPA is made prior to and independent of study participation.
- The participant should not be treated with UPA prior to this study.
- Participants who are willing and able to participate in the collection of patient-reported data, including ePROs and eDiary via apps.
- The participant (legal representative for adolescents) voluntarily signed an informed consent before any study-related activities are conducted.
Who cannot join
- The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation).
- Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.
Trial locations and contacts
38 sites in 1 country.
38 sites in 1 country
China38 sites
Beijing Anzhen Hospital /ID# 273443
Beijing, Beijing Municipality, 100029
China-Japan Friendship Hospital /ID# 274778
Beijing, Beijing Municipality, 100029
Peking University First Hospital /ID# 274865
Beijing, Beijing Municipality, 100034
Peking Unversity Third hospital /ID# 274864
Beijing, Beijing Municipality, 100191
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193
Beijing, Beijing Municipality, 100730
Xiangya Hospital Central South University /ID# 272373
Changsha, Hunan, 410008
West China Hospital of Sichuan University /ID# 268313
Chengdu, Sichuan, 610041
Sichuan Provincial People's Hospital /ID# 268314
Chengdu, Sichuan, 610072
Dalian Dermatosis Hospital /ID# 272495
Dalian, Liaoning, 116041
The First Affiliated Hospital Of Fujian Medical University /ID# 268210
Fuzhou, Fujian, 350005
Guangzhou Dermatology Hospital /ID# 271684
Guangzhou, Guangdong, 510095
Hainan Fifth People's Hospital /ID# 269747
Hainan, Hainan, 200000
Hebei Engineering University Affiliated Hospital /ID# 268660
Handan, Hebei, 200000
Zhejiang Provincial Hospital of Chinese Medicine /ID# 268613
Hangzhou, Zhejiang, 310006
The Second Affiliated Hospital Of Harbin Medical University /ID# 270872
Harbin, Heilongjiang, 150001
Shandong Provincial Hospital /ID# 268661
Jinan, Shandong, 250001
Jining Medical University - Affiliated Hospital /ID# 270873
Jining, Shandong, 272029
The First Affiliated Hospital of Kunming Medical College /ID# 273451
Kunming, Yunnan, 650032
The Affiliated Hospital Of Southwest Medical University /ID# 268207
Luzhou, Sichuan, 646600
Nanjing Drum Tower Hospital /ID# 268616
Nanjing, Jiangsu, 210008
Affiliated Hospital Of Nantong University /ID# 269743
Nantong, Jiangsu, 226001
Ningbo No.6 hospital /ID# 268315
Ningbo, Zhejiang, 315040
Ruijin Hospital /ID# 268658
Shanghai, Shanghai Municipality, 200025
Huashan Hospital Of Fudan University /ID# 270277
Shanghai, Shanghai Municipality, 200040
Shanghai Sixth People'S Hospital /ID# 268617
Shanghai, Shanghai Municipality, 200233
Shanghai Skin Disease Hospital /ID# 268657
Shanghai, Shanghai Municipality, 200443
The People's Hospital of Liaoning Province /ID# 268206
Shenyang, Liaoning, 110016
The First Affiliated Hospital of Soochow University /ID# 269742
Suzhou, Jiangsu, 215006
Taizhou Central Hospital /ID# 268211
Taizhou, Zhejiang, 318000
People's Hospital of Xinjiang Uygur Autonomous Region /ID# 269746
Ürümqi, Xinjiang, 830001
Weifang People'S Hospital /ID# 268659
Weifang, Shandong, 261041
Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 272374
Wuhan, Hubei, 430022
Tongji Hospital /ID# 269745
Wuhan, Hubei, 430030
Changgeng Hospital /ID# 268209
Xiamen, Fujian, 361022
The Affiliated Hospital of Xuzhou Medical College /ID# 268208
Xuzhou, Jiangsu, 221006
People's Hospital of Henan Province /ID# 269744
Zhengzhou, Henan, 450003
The Fifth Affiliated Hospital Of Sun Yat-Sen University /ID# 268618
Zhuhai, Guangdong, 519000
Zhuji People'S Hospital /ID# 268614
Zhuji, Zhejiang, 315000
About this study
Official title: REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin.
Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up to 40 sites in China.
Read more
Participants will receive oral upadacitinib tablets as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 12 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Conditions
- Atopic Dermatitis
- Keywords
- Upadacitinib, Rinvoq
- Medical subject headings
- Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Upadacitinib | Participants will receive upadacitinib as prescribed by their physician according to local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with a dose change
Dose change includes: Changed dose, dose escalation or dose tapering.
Measured: 12 Months
Number of participants with Upadacitinib drug compliance
The participants missed medication, regardless of reason, or incompliance with the prescription as per medical advice are to be recorded in the eDiary, choosing the reason: "Forgot, Self-reduction of medication, interruption because of AE, interruption not due to safety/tolerability, for other reasons".
If no eDiary entries are found within 30 days before the visit, the participant will need to complete the following question in ePRO: timely Upadacitinib intake per medical advice in past 30 days (yes/no); if "no", days-off-drug, intentionally or accidentally, and if "intentionally", reason for incompliance with medical prescription.
Measured: 12 Months
Number of participants with interruption or permanent discontinuation
Interruption: Upadacitinib is temporarily interrupted due to atopic dermatitis disease condition, economic, tolerance, AE, or personal reasons, and the investigator considers there is still possibility of Upadacitinib re-initiating within the patient's study follow-up period.
Discontinuation: Upadacitinib is permanently discontinued for safety or any other reasons, and the investigator considers Upadacitinib will not be used again, at least within the participant's study follow-up period.
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2024
- Study start7 Jun 2024
- Primary completion25 May 2026
- Study completion25 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06421740
- Sponsor's protocol ID
- P24-965
- Acronym
- REACH-AD
- Status last verified
- Aug 2026
- First submitted
- 15 May 2024
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China
- ClinicalTrials.gov ID
- NCT06421740
- Acronym / sponsor ID
- REACH-AD / P24-965
- Conditions
- Atopic Dermatitis
- Keywords
- Upadacitinib, Rinvoq
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 7 Jun 2024 (actual)
- Primary completion
- 25 May 2026 (actual)
- Study completion
- 25 May 2026 (actual)
- First posted
- 20 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin.
Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up to 40 sites in China.
Participants will receive oral upadacitinib tablets as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 12 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Upadacitinib | – | –Participants will receive upadacitinib as prescribed by their physician according to local label. |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
Key inclusion criteria (7 listed)
- Adolescents (body weight >= 40 kg at the Baseline Visit for patients between >= 12 and < 18 years of age) and adults at the time of enrollment.
- Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
- UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC.
- The decision to prescribe UPA is made prior to and independent of study participation.
- The participant should not be treated with UPA prior to this study.
Key exclusion criteria (2 listed)
- The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation).
- Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants with a dose change
Time frame: 12 Months
Dose change includes: Changed dose, dose escalation or dose tapering.
Number of participants with Upadacitinib drug compliance
Time frame: 12 Months
The participants missed medication, regardless of reason, or incompliance with the prescription as per medical advice are to be recorded in the eDiary, choosing the reason: "Forgot, Self-reduction of medication, interruption because of AE, interruption not due to safety/tolerability, for other reasons". If no eDiary entries are found within 30 days before the visit, the participant will need to complete the following question in ePRO: timely Upadacitinib intake per medical advice in past 30 days (yes/no); if "no", days-off-drug, intentionally or accidentally, and if "intentionally", reason for incompliance with medical prescription.
Number of participants with interruption or permanent discontinuation
Time frame: 12 Months
Interruption: Upadacitinib is temporarily interrupted due to atopic dermatitis disease condition, economic, tolerance, AE, or personal reasons, and the investigator considers there is still possibility of Upadacitinib re-initiating within the patient's study follow-up period. Discontinuation: Upadacitinib is permanently discontinued for safety or any other reasons, and the investigator considers Upadacitinib will not be used again, at least within the participant's study follow-up period.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
38 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atopic Dermatitis, run by AbbVie at 38 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with a dose change (time frame: 12 Months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.